Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinfo ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...

Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a ...

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Researchers in China may have uncovered a surprising ally in the fight against sugar cravings and metabolic disorders: a ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Coya Therapeutics (COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory ...

Coya Therapeutics advances COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 RA for a synergistic anti-inflammatory effect.

The ability to regulate one's own food intake is essential to the survival of both humans and other animals. This innate ...

Behavioral and Cognitive Improvement: By acting on brain regions related to appetite and addiction, these drugs not only ...